Conjugates of an IL-2 Moiety and a Polymer
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application PCT/US2011/060408, filed Nov 11, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,861,705 | Conjugates of an IL-2 Moiety and a Polymer In force · High confidence UsedRemaining | Nektar Therapeutics | In force | High confidence | ||
| US 10,960,079 | Conjugates of an IL-2 Moiety and a Polymer In force · High confidence | Nektar Therapeutics | In force | High confidence | ||
| US 11,091,525 | Method of Refolding an INTERLEUKIN-2 (IL-2) Protein In force · High confidence | Nektar Therapeutics | In force | High confidence | ||
| US 12,247,059 | Conjugates of an IL-2 Moiety and a Polymer In force · Medium confidence | Nektar Therapeutics | In force | Medium confidence | ||
| Application 17/003,847 | Conjugates of an IL-2 Moiety and a Polymer Abandoned Abandoned Nov 2, 2023 | Nektar Therapeutics | Abandoned | Abandoned Nov 2, 2023 | ||
| Application 19/047,443 | Conjugates of an IL-2 Moiety and a Polymer Pending Not granted | Nektar Therapeutics | Pending | Not granted |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Nektar Therapeutics.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.